International Journal of Pharmaceutical and Phytopharmacological Research
ISSN (Print): 2250-1029
ISSN (Online): 2249-6084
Controlled-release systems regulate drug plasma concentration after administration through pre-determined patterns over a fixed period. The release rate should determine drug absorption and concentration. These formulations reduce daily dosing frequency. This article discusses ideal requirements, advantages, properties, and approaches for developing controlled-release formulations to improve drug delivery. This involves delivering drugs at a pre-set rate for a limited period, either locally or systemically. This method, utilizing drug-encapsulating devices, offers advantages over traditional methods, including tailored release rates, drug protection, and increased patient comfort. Controlled-release drug delivery systems maintain a uniform plasma concentration within the therapeutic range, minimizing side effects and administration frequency. Oral sustained-release products optimize drug properties, reducing dosing frequency and ensuring maximum drug utility, reduced side effects, and quicker cure or control conditions. Technological advancements have revolutionized medication methods with controlled drug delivery systems, offering benefits like multiple dosing and single dosing. Oral CRDD provides continuous oral delivery of drugs at predictable kinetics for a predetermined period, targeting specific regions within the gastrointestinal tract for local or systemic action. This technique reduces drug administration frequency and maintains constant drug levels in the patient’s bloodstream, increasing its therapeutic effectiveness.
INTRODUCTION
Controlled drug delivery systems offer benefits such as desired drug levels. However, they also face potential disadvantages such as toxicity, undesirable by-products, surgery, patient discomfort, and potential side effects [1]. Controlled-release systems are expensive compared to traditional pharmaceuticals, but ideal systems should be motionless, biocompatible, powerful, comfortable, safe, and easy to administer, and aim to maintain high drug levels over time.
The ideal polymer balances swelling, erosion, and dissolution processes. However, achieving high gel-state viscosity and maintaining a constant gel layer for linear drug release over prolonged periods remains a challenge due to various dynamic phases in polymer relaxation, disentanglement, and erosion [2, 3]. Controlled-release drug delivery systems maintain plasma concentration within the therapeutic range, minimizing side effects and administration frequency by providing uniform drug concentration to the absorption site [4, 5].
Sustained release systems aim to reduce dosing frequency or increase drug effectiveness by localizing at the action site, reducing the required dose, or providing uniform drug delivery. These systems provide medications over extended periods, while controlled release systems provide therapeutic control. Sustained-release dosage forms are increasingly being studied for better patient compliance and decreased misuse. Research in this field has yielded numerous discoveries, with new and sophisticated controlled release and sustained release delivery systems always being developed and tested [1, 6]. The introduction of orally administered once-daily products raises concerns about testing and clinical assessment. This presentation provides an overview of extended-release products, their theoretical base, typical formulation approaches, and current issues in the field [1].
Historically, alkaline compounds or buffers have been used in solid oral formulations of acidic drugs to overcome dissolution rate-limited absorption [7]. However, no strategy has been developed for a simple, compressible, monolithic, and controlled-release system with zero-order kinetics, primarily aimed at minimizing gastrointestinal tract and pH solubility dependency [8].
This article discusses ideal requirements, advantages, properties, and approaches for developing controlled-release formulations to improve drug delivery. This involves delivering drugs at a pre-set rate for a limited period, either locally or systemically.
RESULTS AND DISCUSSION
Controlled-release dosage form
The USP defines modified-release forms as those that use drug-release characteristics to achieve therapeutic or convenience not offered by conventional dosage forms [9]. Extended-release dosage forms allow for a two-fold reduction in dosing or a significant increase in patient compliance. Most marketed monolithic oral extended-release dosage forms fall into two technologies: hydrophilic, hydrophobic, or inert matrix systems, and reservoir (coated) systems. These systems involve simple diffusion/erosion systems or osmotic systems, where the drug core is enclosed within a polymer membrane [10, 11].
Polymers used in control drug delivery system
Polymers play a crucial role in drug delivery, serving as binders in tablets, and viscosity. Flow-controlling agents in liquids, suspensions, and emulsions [12]. They can also be used as film coatings to disguise drug taste, enhance stability, and modify release characteristics. Controlled drug delivery (CDD) involves combining a polymer with a drug or active agent to release the active agent in a predesigned manner, achieving more effective therapies and reducing under and overdosing (Figure 1) [4, 13].
|
|
|
Figure 1. Polymer-controlled drug delivery. |
Characteristics of drugs suitable for controlled release
Advantages
Disadvantages
Types of controlled drug delivery systems
Controlled drug delivery systems are broadly classified as follows:
Classification
The mechanism to obtain sustained and controlled release of drugs [35], they are classified as follows:
The diffusion process involves drug molecules moving from higher to lower concentrations, as per Fick's law. The release charge of a drug depends on diffusion past the membrane barrier [36].
Reservoir type: Delivery systems akin to reservoirs are manufactured [37]. This guarantees that the medication exits the delivery vehicle gradually. The partitioning of the drug molecules within the polymeric membrane is the rate-limiting step during the release process in various kinds of delivery systems (Figure 2) [38, 39].
Matrix: The controlled release matrix system delivers drugs at a predetermined rate at the specified time, aiming to achieve therapeutic plasma levels through desirable delivery profiles (Figure 2) [40].
|
|
|
|
a) |
b) |
|
Figure 2. Schematic diagram of reservoir and matrix systems |
|
High aqueous solubilized drugs face a dissolution rate [41]. Controlling dissolution can be achieved by slowing it down, incorporating it in an insoluble polymer, or coating it with polymeric materials [42]. The rate-limiting step is diffusion across the aqueous boundary layer [43, 44].
Encapsulation systems: By using slow-dissolving polymers, microencapsulation procedures coat or encapsulate drug particles [45, 46]. The coating’s thickness and solubility determine how quickly it dissolves.
Matrix systems: Matrix dissolution systems are the most commonly used technique in controlled delivery systems and involve the API being homogeneously distributed throughout a polymer matrix [47]. As the polymer matrix dissolves (typically via an erosion-mediated process), drug molecules are released into the external environment [48].
Its rate control is obtained by the penetration of water into the system [49].
Swelling-controlled systems: Swelling-controlled release systems absorb body fluids and swell, increasing solvent content and polymer mesh size and allowing drug diffusion through swollen networks [50, 51].
Osmotic controlled release systems: Every osmotic medication delivery method has an osmotic core and a semi-permeable membrane that regulates water flow [52]. They only have one orifice, and the medication is only ever released as a solution [53]. Only works with medications that dissolve in water. Drug release has kinetics [54] that are zero-order (Figure 3).
|
|
|
Figure 3. Schematic diagram of EOP osmotic system. |
Applications
Controlled-release medications are beneficial for patients with chronic diseases such as diabetes [55], hypertension [56], asthma [57], and epilepsy [58], as well as neurological disorders like Alzheimer’s and Parkinson's [59, 60]. They are also used in hormone therapy [61], chronic disease management [62], and pain management [63], providing sustained release of pain-relieving medications [64] for improved control and reduced side effects [65]. Controlled drug delivery systems (CDDS) are used in various fields, including cancer treatment [66], ophthalmology [67], neurological disorders [68], cardiovascular diseases [69], antibiotic therapy [70], hormone replacement therapy [71], transplantation medicine [72], and pediatric medicine [73]. CDDS provide prolonged relief [74], reduce the need for frequent dosing, and minimize the risk of addiction. They target tumors, improve treatment efficacy, and minimize systemic side effects [75]. CDDS are also used in ophthalmology for sustained drug release, neurological disorders like Parkinson’s disease and epilepsy, and antibiotic therapy for localized infections [76].
Polymers
Polymers play a significant role in controlled drug delivery systems due to their versatility in modulating drug release rates, targeting specific tissues, and protecting drugs from degradation [75]. Here are a few common types of polymers used in controlled-release drug delivery:
These polymers can be tailored in terms of molecular weight, composition [91], and structure to achieve specific release profiles, site-specific targeting, and reduced toxicity [92]. Controlled-release drug delivery systems offer numerous advantages over conventional dosage forms, including improved patient compliance, reduced side effects, and enhanced therapeutic efficacy [93].
CONCLUSION
Dosage forms combine drugs and excipients to enhance stability and taste. Conventional dosage forms struggle with fluctuating plasma drug levels, requiring high dosing frequency and patient compliance. Controlled drug delivery systems improve bioavailability, release, and maintain plasma levels with minimal side effects. These systems include dissolution, diffusion, water penetration, and chemically controlled delivery. Stimuli-responsive delivery systems are useful in disease conditions. Future drug delivery focuses on patient-specific therapy using microfluidic-based, 3D printed devices, and CRISPR cas9-based systems. Modern technologies, including targeted concepts, have revolutionized oral controlled delivery, offering advantages over conventional dosage forms. This optimizes drug properties, reduces dosing frequency, and maximizes drug utility through uniform plasma concentration, making it a popular and convenient delivery method.
Acknowledgments: The authors are thankful to the management of the CMR College of Pharmacy, Medchal, Hyderabad for their support and encouragement.
Conflict of interest: None
Financial support: None
Ethics statement: None
